# FENC catalysts: FENNEC PHARMACEUTICALS INC. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/fenc/catalysts

> FENNEC PHARMACEUTICALS INC. (FENC) has no upcoming catalysts in this calendar. The latest recorded is the cisplatin trial start, September 17, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for FENC?

FENNEC PHARMACEUTICALS INC. (FENC) has no upcoming catalysts in this calendar. The latest recorded is the cisplatin trial start, September 17, 2026. SEC Form 8-K: "On September 17, 2026, Fennec Pharmaceuticals Inc. (the "Company") announced positive results from the investigator-initiated Phase 2 STS-J01 clinical study of PEDMARK® in Japan, which met its primary endpoint and demonstrated significant hearing protection without evidence of interference with cisplatin antitumor activity." [Calendar and source filings](https://sec-api.dev/companies/fenc/catalysts)

Source: SEC Form 8-K, accession 0001104659-26-108565, https://www.sec.gov/Archives/edgar/data/1211583/000110465926108565/fencf-20260917x8k.htm (retrieved 2026-11-12). Last confirmed 2026-09-17. Cite: https://sec-api.dev/companies/fenc/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | FENNEC PHARMACEUTICALS INC. |
| Ticker | FENC (Nasdaq) |
| SEC CIK | 1211583 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/fenc |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| August 10, 2020 | [Pedmark (sodium thiosulfate) complete response letter (CRL)](https://sec-api.dev/pdufa/thiosulfate) | FENC |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22212937_2023_Orig1s000OtherActionLtrs.pdf%22)) |
| November 26, 2021 | [Pedmark (sodium thiosulfate) complete response letter (CRL)](https://sec-api.dev/pdufa/thiosulfate) | FENC |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22212937_2023_Orig1s000OtherActionLtrs.pdf%22)) |
| September 20, 2022 | [Cisplatin FDA approval](https://sec-api.dev/pdufa/cisplatin) | FENC |  | completed, approved | "On September 20, 2022 we received approval from the U.S. Food and Drug Administration ("FDA") for PEDMARK® (sodium thiosulfate injection) to reduce the risk of ototoxicity associated with cisplatin in pediatric patients one month of age and older with localized, non-metastatic solid tumors." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1211583/000110465925113422/tm2531484-1_424b5.htm)) |
| September 20, 2022 | [PEDMARK (pedmark) FDA approval](https://sec-api.dev/pdufa/pedmark) | FENC |  | completed, approved | "On September 20, 2022, we received approval from the FDA for PEDMARK® (sodium thiosulfate injection)." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1211583/000155837025003710/fencf-20241231x10k.htm)) |
| March 10, 2025 | [FENNEC PHARMACEUTICALS INC. earnings report](https://sec-api.dev/companies/fenc/catalysts) | FENC |  | completed | "FENNEC PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL-YEAR 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1211583/000155837025002599/fencf-20250310xex99d1.htm)) |
| December 2, 2025 | [PEDMARK (pedmark) trial start](https://sec-api.dev/pdufa/pedmark) | FENC |  | completed | "2025 - Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced positive topline results from the investigator-initiated Phase 2/3 STS-J01 clinical trial evaluating PEDMARK® (sodium thiosulfate injection)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1211583/000110465925117697/tm2532518d1_ex99-1.htm)) |
| December 2, 2025 | [Cisplatin topline data readout](https://sec-api.dev/pdufa/cisplatin) | FENC |  | completed, positive | "On December 2, 2025, Fennec Pharmaceuticals Inc. issued a news release and announced positive topline results from the investigator-initiated Phase 2/3 STS-J01 clinical trial evaluating PEDMARK® (sodium thiosulfate injection) for the reduction of cisplatin-induced ototoxicity in pediatric and adolescent and young adult (AYA) patients with non-metastatic solid tumors in Japan." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1211583/000110465925117697/tm2532518d1_8k.htm)) |
| December 2, 2025 | [PEDMARK (pedmark) topline data readout](https://sec-api.dev/pdufa/pedmark) | FENC |  | completed, positive | "2025 - Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced positive topline results from the investigator-initiated Phase 2/3 STS-J01 clinical trial evaluating PEDMARK® (sodium thiosulfate injection)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1211583/000110465925117697/tm2532518d1_ex99-1.htm)) |
| December 2, 2025 | [Cisplatin trial start](https://sec-api.dev/pdufa/cisplatin) | FENC |  | completed | "On December 2, 2025, Fennec Pharmaceuticals Inc. issued a news release and announced positive topline results from the investigator-initiated Phase 2/3 STS-J01 clinical trial evaluating PEDMARK® (sodium thiosulfate injection) for the reduction of cisplatin-induced ototoxicity in pediatric and adolescent and young adult (AYA) patients with non-metastatic solid tumors in Japan." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1211583/000110465925117697/tm2532518d1_8k.htm)) |
| March 24, 2026 | [FENNEC PHARMACEUTICALS INC. earnings report](https://sec-api.dev/companies/fenc/catalysts) | FENC |  | completed | "FENNEC PHARMACEUTICALS REPORTS FOURTH Quarter AND FULL YEAR 2025 FINANCIAL RESULTS and provides business update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1211583/000110465926033885/fencf-20260324xex99d1.htm)) |
| March 24, 2026 | [Cisplatin trial start](https://sec-api.dev/pdufa/cisplatin) | FENC |  | completed | "STS-J01 in Japan: In December, Fennec announced positive topline results from the investigator-initiated Phase 2/3 STS-J01 clinical trial evaluating PEDMARK® for the reduction of cisplatin-induced ototoxicity in pediatric and adolescent and young adult (AYA) patients with non-metastatic solid tumors in Japan." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1211583/000110465926033885/fencf-20260324xex99d1.htm)) |
| September 17, 2026 | [PEDMARK (pedmark) trial start](https://sec-api.dev/pdufa/pedmark) | FENC |  | completed | "Fennec Pharmaceuticals Announces ORAL PRESENTATION OF DETAILED Results From Investigator-Initiated Phase 2 STS-J01 Clinical Study of PEDMARK® in Japan AT SIOP 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1211583/000110465926108565/fencf-20260917xex99d1.htm)) |
| September 17, 2026 | [Cisplatin trial start](https://sec-api.dev/pdufa/cisplatin) | FENC |  | completed | "On September 17, 2026, Fennec Pharmaceuticals Inc. (the "Company") announced positive results from the investigator-initiated Phase 2 STS-J01 clinical study of PEDMARK® in Japan, which met its primary endpoint and demonstrated significant hearing protection without evidence of interference with cisplatin antitumor activity." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1211583/000110465926108565/fencf-20260917x8k.htm)) |

## Drugs

- [Cisplatin](https://sec-api.dev/pdufa/cisplatin): cisplatin-ineligible head and neck cancer
- [PEDMARK (pedmark)](https://sec-api.dev/pdufa/pedmark): 
- [Pedmark (sodium thiosulfate)](https://sec-api.dev/pdufa/thiosulfate): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/fenc/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "FENC catalysts: FENNEC PHARMACEUTICALS INC. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/fenc/catalysts

```bibtex
@misc{secapidev_companies_fenc_catalysts_20261116,
  title        = {FENC catalysts: FENNEC PHARMACEUTICALS INC. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/fenc/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_fenc_catalysts_20261116","title":"FENC catalysts: FENNEC PHARMACEUTICALS INC. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/fenc/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
